BOSTON, MA & RESTON, Va.–(BUSINESS WIRE)–Outcome Capital (www.outcomecapital.com) today announced that Steven Wardell and Karl Hess have joined the firm as Senior Advisors for its...
Read MoreRESTON, Va.–(BUSINESS WIRE)–Outcome Capital, an advisory and investment banking firm that serves middle market growth companies in IT services, software, managed services, ADGS, healthcare and...
Read MoreNavigating uncharted waters, biotech investors, executives and entrepreneurs are finding unique challenges (and opportunities) in a COVID-19 world. Contributing author, Outcome Capital’s Dr. Oded Ben-Joseph, Managing Director and Co-Founder of the Life Sciences Practice.
Read MoreThe Contract Waterfall: Important Financial Tool in a Federal Government Contractor’s Toolset The contract waterfall plays an important role for both the buyer and the...
Read MoreOutcome Capital Advises Forward Photonics in its Sale April 24, 2020, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth...
Read MoreOutcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies...
Read MoreOutcome Capital and Partners HealthCare Innovation Collaborate through the Innovation Fellows Program to Provide Experience in the Business of Science June 4, 2019, Boston, MA...
Read MoreOutcome Capital Advises Whisker Labs in the Sale of its Energy Management Business to Resideo Technologies May 29, 2019, Reston, VA Outcome Capital, an investment...
Read MoreOutcome Capital Announces Meridian Bioscience Has Acquired GenePOC May 1, 2019, BOSTON, MA –(BUSINESS WIRE)– Outcome Capital, a specialized investment banking firm that serves middle...
Read MorePartnerships and the move to value dominated the chatter at the BIO International Convention's 25th annual partnering meeting on Monday in the life science hub of Boston.
Read MoreInvestors want to know: Will Big Pharma go bargain hunting, do a little M&A? Will it lift my biotech portfolio out of the gutter? Multiple factors are always at work. At the most basic level, pharma still needs to acquire new products to stay afloat. Little biotechs who create things need to be acquired, or go public, to reward their investors. Those facts never change. But there’s another powerful, and dark, force creating havoc in many biotech boardrooms. People who have witnessed it don’t like to talk about it. When they do, it’s in hushed tones...
Read MoreOn August 4, 2006, Outcome Capital announced that it had acted as exclusive financial advisor to East West Mortgage on the sale of three websites...
Read MoreWould you like to learn more about working with Outcome Capital or discuss your specific needs?